A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Hoffmann-La Roche
Hoffmann-La Roche
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Seagen Inc.
Dana-Farber Cancer Institute
OHSU Knight Cancer Institute
Pfizer
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
Medical College of Wisconsin
Leap Therapeutics, Inc.
University of Alabama at Birmingham
Hoosier Cancer Research Network
Georgetown University
University of California, San Francisco
Georgetown University
Boehringer Ingelheim
National Institutes of Health Clinical Center (CC)
Alliance for Clinical Trials in Oncology
Stanford University
Georgetown University
Novartis
M.D. Anderson Cancer Center
Academic and Community Cancer Research United
Servier
Federation Francophone de Cancerologie Digestive
Hoffmann-La Roche
Pierre Fabre Medicament
ETOP IBCSG Partners Foundation
Stanford University
Jiangsu HengRui Medicine Co., Ltd.
Herlev Hospital
Sumitomo Pharma America, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Southern California
M.D. Anderson Cancer Center
University of Nebraska
University of Nebraska
Medical College of Wisconsin
Seagen Inc.
Eisai Inc.
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Barbara Ann Karmanos Cancer Institute
Puma Biotechnology, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC
University of Pittsburgh